EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
EPRS was delisted on the 3rd of August, 2016.
41 hedge funds and large institutions have $81M invested in EPIRUS BIOPHARMACEUTICALS INC COM in 2015 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 14 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
13% less funds holding
Funds holding: 47 → 41 (-6)
33% less capital invested
Capital invested by funds: $120M → $81M (-$39.4M)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$5.07M |
| 2 |
B
Bailard
Foster City,
California
|
+$1.68M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$290K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$276K |
| 5 |
Millennium Management
New York
|
+$249K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Forward Management
San Francisco,
California
|
-$1.38M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$446K |
| 3 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$428K |
| 4 |
CAD
Craig A. Drill
|
-$413K |
| 5 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$392K |
EPRS Hedge Fund Activity: Q2 2015 in Review
41 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) for Q2 2015, worth a combined $81M — down 33% from $120M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of EPRS and 8 opened new positions — a net loss of 6 holders — while 9 trimmed existing stakes and 14 added.
The largest buyer was Consonance Capital Management, adding an estimated $5.07M. The largest seller was Forward Management, exiting entirely with an estimated $1.38M sold.
- 41 institutional investors held EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) as of Q2 2015, down from 47 in Q1 2015.
- Funds reported $81M of EPIRUS BIOPHARMACEUTICALS INC COM stock for Q2 2015, down 33% quarter-over-quarter.
- 8 funds opened new EPIRUS BIOPHARMACEUTICALS INC COM positions in Q2 2015 and 14 closed out, a net change of -6 holders.
- The largest EPIRUS BIOPHARMACEUTICALS INC COM buyer in Q2 2015 was Consonance Capital Management, an estimated $5.07M added.
- The largest EPIRUS BIOPHARMACEUTICALS INC COM seller in Q2 2015 was Forward Management, an estimated $1.38M sold.
Based on aggregated 13F filings for Q2 2015.